Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clene Inc. (CLNN : NSDQ)

• Company Description    Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY. Number of Employees: 76

• Price / Volume Information    Yesterday's Closing Price: $5.87 Daily Weekly Monthly 20 Day Moving Average: 142,077 shares Shares Outstanding: 10.33 (millions) Market Capitalization: $60.66 (millions) Beta: 0.88 52 Week High: $13.50 52 Week Low: $2.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.70% -18.65% 12 Week -37.69% -38.52% Year To Date 10.55% -5.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6550 SOUTH MILLROCK DRIVE SUITE G50 - SALT LAKE CITY,UT 84121 USA ph: 801-676-9695 fax: - kgardner@lifesciadvisors.com https://clene.com

• General Corporate Information    Officers Robert Etherington - President; Chief Executive Officer and Director David J. Matlin - Chairman of the Board Morgan R. Brown - Chief Financial Officer Arjun Desai - Director Jonathon T. Gay - Director Peer Information Clene Inc. (CORR.) Clene Inc. (RSPI) Clene Inc. (CGXP) Clene Inc. (BGEN) Clene Inc. (GTBP) Clene Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 185634201 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 10.33 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.88 Market Capitalization: $60.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 283.46 EPS Growth vs. Year Ago Period: 30.33% vs. Previous Quarter: -8.97% Sales Growth vs. Year Ago Period: -82.76% vs. Previous Quarter: -44.44% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -140.71 06/30/25 - -125.49 Current Ratio 12/31/25 - - 09/30/25 - 1.53 06/30/25 - 1.58 Quick Ratio 12/31/25 - - 09/30/25 - 1.52 06/30/25 - 1.57 Operating Margin 12/31/25 - - 09/30/25 - -15,959.35 06/30/25 - -11,665.04 Net Margin 12/31/25 - - 09/30/25 - -14,250.47 06/30/25 - -10,386.36 Pre-Tax Margin 12/31/25 - - 09/30/25 - -14,250.47 06/30/25 - -10,386.36 Book Value 12/31/25 - - 09/30/25 - -1.23 06/30/25 - -1.03 Inventory Turnover 12/31/25 - - 09/30/25 - 0.62 06/30/25 - 0.72 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©